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ABSTRACT
Purpose Near real-time vaccine safety surveillance (NRTVSS) is an option for post-licensure vaccine safety assessment. NRTVSS
requires timely recording of outcomes in the database used. Our main objective was to examine recording delays in the Clinical Practice
Research Datalink (CPRD) for outcomes of interest for vaccine safety to inform the feasibility of NRTVSS using these data. We also
evaluated completeness of recording and further assessed reporting delays for hospitalized events in CPRD.
Methods We selected Guillain–Barré syndrome (GBS), Bell’s palsy (BP), optic neuritis (ON) and febrile seizures (FS), from January 2005
to June 2014. We assessed recording delays (e.g. due to feedback from specialist referral) in stand-alone CPRD by comparing the event and
system dates and excluding delays >1 year. We used linked CPRD-hospitalization data to further evaluate delays and completeness of
recording in CPRD.
Results Among 51 220 patients for the stand-alone CPRD analysis (GBS: n = 830; BP: n = 12 602; ON: n = 1720; and FS: n = 36 236),
most had a record entered within 1 month of the event date (GBS: 73.6%; BP: 93.4%; ON: 76.2%; and FS: 85.6%). A total of 13 482
patients, with a ﬁrst record in hospital, were included for the analysis of linked data (GBS: n = 678; BP: n = 4060; ON: n = 485; and FS:
n = 8321). Of these, <50% had a record in CPRD after 1 year (GBS: 41.3%; BP: 22.1%; ON: 22.4%; and FS: 41.8%).
Conclusion This work shows that most diagnoses in CPRD for the conditions examined were recorded with delays of ≤30 days, making
NRTVSS possible. The pattern of delays was condition-speciﬁc and could be used to adjust for delays in the NRTVSS analysis. Despite low
sensitivity of recording, implementing NRTVSS in CPRD is worthwhile and could be carried out, at least on a trial basis, for events of
interest. © 2017 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd.
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INTRODUCTION
The Clinical Practice Research Datalink (CPRD) is a
UK primary care database widely used for epidemio-
logical research, including monitoring disease rates
over time and assessing the post-licensure safety of
several vaccines using epidemiological designs.1–9
Near real-time vaccine safety surveillance (NRTVSS)
using electronic health records is a post-licensure vac-
cine surveillance tool that involves monitoring rates
of adverse events over time to identify changes associ-
ated with vaccine use. NRTVSS is ideally started at the
time a vaccine is introduced in a population by looking
at data at repeated time points to ensure timely signal
identiﬁcation. This type of surveillance is now used
by the Vaccine Safety Datalink in the USA and has
been implemented by a few other countries.10 In the
UK, NRTVSS has been carried out using spontaneous
reports to calculate the observed number of events and
CPRD data to calculate the expected number of
events.11 However, CPRD data have not been used as
the sole data source to perform NRTVSS.
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The CPRD data are currently updated monthly and
are therefore a potential data source for implementing
NRTVSS. For near real-time surveillance, timeliness
is paramount. One way of dealing with delays is to
delay the analysis until sufﬁcient data accrue. A more
timely approach12 is to know how long it takes for data
to accrue and then use the pattern of delays to adjust
the expected number of events.
Data accrual delays in CPRD can be due to the
following: (i) delays in making the diagnosis after an
initial consultation, (ii) practices receiving and record-
ing diagnoses made at secondary care and (iii) delays
in uploading the data for researchers. Different out-
comes of interest might have different sources and
levels of delay, depending, for example, on whether
the onset of the condition is acute or insidious and
the healthcare setting in which it is diagnosed and
managed.13 Given CPRD’s structure, it is likely that
an acute condition that is usually diagnosed and man-
aged by general practitioners (GPs) will accrue more
quickly than a condition diagnosed and managed in
hospital. Conversely, a more insidious condition and
which tends to be diagnosed in secondary care might
take longer to accrue. Understanding recording delays,
by knowing the time it takes for data to accrue and
how this differs by condition, helps to determine the
feasibility of implementing NRTVSS in CPRD. In this
paper, we focus on delays in practices recording diag-
noses made elsewhere (aforementioned scenario ii).
It is also important to understand the sensitivity of
CPRD for capturing outcomes of interest. Feedback
from secondary care (e.g. hospital admissions and
outpatient consultations) may not be completely
captured as coded diagnoses in CPRD, for example,
if GPs do not code these events but simply scan in
hospital letters without adding diagnostic codes to
the patient record. The information from hospital
admissions in England is recorded in the Hospital
Episode Statistics (HES) database and linked to
CPRD for a subset of practices. Previous studies have
shown that the use of linked data (including primary
and secondary care information) improves sensitivity
of diagnoses.14–16 However, these linkages are cur-
rently updated too infrequently to allow their use for
surveillance purposes. To the best of our knowledge,
no previous studies have investigated completeness
of recording for conditions of interest for NRTVSS
that are typically diagnosed in secondary care such
as Guillain–Barré syndrome (GBS).
Our main objective was thus to examine recording
delays for selected conditions, due to practices receiv-
ing and recording diagnoses made at secondary care,
in stand-alone CPRD, to inform the feasibility of
implementing NRTVSS in England using these data.
Secondary objectives were to further assess delays
and evaluate completeness of recording of diagnoses
in CPRD using linked hospitalization data.
METHODS
Data sources
For our main analysis, we used data from CPRD,
which comprises anonymized UK primary care health
records for >11.3 million patients from 674 general
practices, with information on demographics, diagno-
sis, therapies, vaccines, health-related behaviours and
referrals to secondary care.1 Patient information is
recorded using Read codes, and when a new record
is entered, the software automatically assigns it the
current date, the system date. Practice staff also enters
an event date, the date generally considered to
represent the time the event has occurred. Monthly
updates of CPRD data include the date information
was last collected from each practice (last collection
date).13
Despite being assigned when new records are
entered, the system date can be changed when mass
transfer of records occurs. These might occur when
(Rachael Williams, personal communication) (1) the
practice changes software to Vision (and joins
CPRD) or updates their version of Vision: previous
system dates will be updated for all patients to the
date the change has occurred; (2) patients’ records
are transferred from their previous practice (or an in-
ternal transfer of a patient occurs within a practice);
the system dates for that patient’s records will then
all be changed to the date the transfer occurred.
Our secondary analysis used CPRD–HES linked
data, which includes patient-level information from
58% of all CPRD practices.1 HES data are coded
using International Classiﬁcation of Diseases, version
10 (ICD-10), and each hospitalization includes ≥1
episode, corresponding to the time a patient is
under the care of a single consultant.17 Information
available includes date of hospital admission and
discharge and, for each episode, a starting date
(episode date).
Outcomes
We selected four outcomes of interest for NRTVSS10:
GBS, Bell’s palsy (BP), optic neuritis (ON) and febrile
seizures (FS). These represent different characteristics
that might affect delays; GBS is an acute condition,
diagnosed and managed in hospital; BP is typically
diagnosed and managed by GPs; ON is a more
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insidious condition, likely to be diagnosed in
outpatient hospital settings; and FS can be diagnosed
and managed in both primary and secondary care.10
For each outcome, a speciﬁc and a broader (potentially
more sensitive but less speciﬁc) code lists were
considered (Appendix A). These different versions
were used to explore the effect of imperfect validity
of different code lists to identify the outcomes. It has
been previously suggested that for NRTVSS, a more
sensitive code list generates more timely signals.18
We thus considered the broader code list in our main
analysis and the speciﬁc code list in a sensitivity
analysis.
Analysis
System dates and event dates were compared to assess
delays in recording. To avoid overestimation of delays
because of mass transfers of system dates to later
dates, we ﬁrst studied which records were likely to
have been part of such transfers and excluded these
from remaining analyses.
We assumed that (i) an unusually high number of
records with the same system date was due to a mass
transfer; (ii) mass transfers are infrequent, so only a
small proportion of patients will have records af-
fected by mass transfers; (iii) there is a threshold
number of repeated system dates above which mass
transfers can be identiﬁed. To identify this threshold,
we created a within-patient proportion of records
with the same system date used s times (psi), using
eligible patient records from the clinical, test, referral
and immunization ﬁles. psi is given by tsi/ri, where tsi
is the number of records with a given number of re-
peat system dates and ri the total number of records
for that patient. For example, if we consider a patient
with a total of 300 records and if this patient has
four records registered on one shared system date
and four others on a different shared system date,
p4 is given by 8/300≈0.03. This means that 3% of
all this patient’s records are recorded in blocks of
four records.
The patient-level psi was averaged across all patients
(aps ¼ ∑ni¼1psi=n). This average proportion of records
with the same system date s was displayed graphically,
and we selected candidate thresholds, on the basis of
our assumptions about mass transfers.
For each threshold, we took a sample of 10 pa-
tients with that number of repeated dates (e.g. if
threshold = 100, we selected the 100 records with
the same system date for 10 patients). We then
looked at these records to assess the likelihood that
they had been involved in mass transfers. We
considered that records with the same system dates
that had codes that could feasibly refer to the same
condition or a related procedure/test result and which
all had the same event date were likely to have been
entered on the same day. Conversely, if the codes
were unrelated, with varying event dates, this would
suggest a mass transfer. To evaluate the inﬂuence
of the ﬁnal threshold decision, we calculated the per-
centage of the outcomes assigned as mass transfers
and excluded using the selected threshold.
After excluding system dates likely to have been
part of mass transfers, we used a forward approach
to assess delays, that is, considering the time from
the event date (the assumed date of diagnosis) until
the system date (the date the diagnosis was entered
in the practice system). Delays were calculated as
the difference between the system and event dates
(Figure 1(A)). We excluded diagnoses with a delay
>1 year as these would be of limited utility for
NRTVSS and could be ignored if NRTVSS was only
based on events recorded within a year. To give
enough time for data to accrue, we considered re-
cords with an event data up to June 2014 (using
CPRD data released in July 2015). Diagnoses within
a year of registration (6 months if aged <1 year)
with the practice were excluded to avoid counting
past diagnoses recorded retrospectively.19 We
described delays in terms of their cumulative distri-
bution and further described these by year of diagno-
sis to assess whether this distribution was constant
over time.
The secondary analysis focused on completeness
and delays in recording for patients with an outcome
of interest in HES. We considered a cohort of patients
with an outcome ﬁrst recorded in HES. Patients were
followed up from the hospital episode date in which
the outcome was ﬁrst recorded until they had an out-
come in CPRD (noting the system date) or were cen-
sored (earliest of date of death, date of leaving the
practice, last collection date or July 2015) (Figure 1
(B).). We excluded patients with a previous record of
the outcome in CPRD, as these would be captured
by a system on the basis of CPRD. We conducted a
sensitivity analysis to evaluate the effect of adding
these patients. Patients with diagnoses within a year
of their registration date (6 months if aged <1 year)
with the practice were also excluded, unless a relevant
diagnosis was made in HES during that period (as the
latter is not subject to retrospective recording of this
type). Kaplan–Meier analysis of the time until
recording the condition in CPRD was used to describe
completeness and delays, truncating the curves at
1 year (considered the period of interest for NRTVSS).
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RESULTS
Analysis of mass transfers
We identiﬁed 54 252 eligible patients for the mass
transfer analysis, with 24 905 375 records. Repeated
system dates ranged from 1 to 3958. Figure 2 shows
the proportion (and cumulative proportion) of records
with a unique date, ranging from 2 to 3958 on the
same date, averaged across patients. The average pro-
portion of records with repeated dates decreased until
50 records, after which it stabilized. The vast majority
(Figure 2 bottom) of records were recorded at the same
time as <49 other events.
We thus selected 50, 100 and 150 as candidate
thresholds, which resulted in losses of 7.7%, 4.5%
and 3.1% of records, respectively. Some of the code
lists with 50 repeated dates were a mixture of blood
tests and diagnosis codes, all with the same event
date. These were considered a plausible combination
of codes to have been entered on the same system
Figure 2. Average proportion (top) and cumulative average proportion of repeated system dates (number of records is represented in the logarithmic scale)
Figure 1. Schematic representation of the analysis undertaken for describing recording delays in CPRD (A) and completeness and delays in HES-CPRD
linked data (B). (A) includes patients with no delay (1), varying delays (2 and 3) and those who were excluded because of having a delay of more than a year
(4). (B) includes a censored patient because of death (1), patients with varying delays (2 and 3) and a patient with a delay of more than 1 year, included in the
analysis but not displayed in the Kaplan–Meier curves. CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics
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date. On the other hand, all the lists of 100 and 150
codes were for different conditions, with different
event dates. We interpreted this as highly suggestive
of a mass transfer and therefore selected 100 as the
threshold. This reduced cases by 2.3%, 1.5%, 2.4%
and 1.5% for GBS, BP, ON and FS, respectively.
After excluding records deemed to be mass transfers,
we assessed delays in stand-alone CPRD for 53 414
patients (GBS: n = 905; BP: n = 13 234; ON:
n = 1837; and FS: n = 37 625).
Recording delays in stand-alone Clinical Practice
Research Datalink
We further excluded records with delays>1 year (% of
exclusions: GBS, 8.3%; BP, 4.8%; ON, 6.4%; and FS,
3.7%). Our ﬁnal analysis included 51 220 patients
(GBS: n = 830; BP: n = 12 602; ON: n = 1720; and
FS: n = 36 236). Table 1 summarizes gender, age and
year of event date for these patients.
Table 2 and Figure 3 present the cumulative
distribution of data accrual lags by condition in
CPRD, deﬁned as the time from event date to sys-
tem date. Most diagnoses were recorded within a
month (73.6% (GBS); 93.4% (BP)). BP had the
highest percentage of records with identical system
and event dates (72.0%), while ON had the lowest
(27.8%). BP and FS records accrue more quickly
than GBS and ON. These differences occur mainly
(but not entirely) until 10 weeks after the event
date, after which data accrual seemed to stabilize.
Using a more speciﬁc code list yielded similar
patterns (Appendix B). These patterns were con-
stant over time (Appendix C).
Comparison of Hospital Episode Statistics–Clinical
Practice Research Datalink
We included 13 482 patients (GBS: n = 678; BP:
n = 4060; ON: n = 485; FS: n = 8321) with a ﬁrst out-
come recorded in HES. Table 3 shows the characteris-
tics of included patients and completeness of recording
in CPRD. Age and sex distributions for GBS and FS
were similar to those observed for the stand-alone data.
BP and ON patients in HES were older (mean age: BP:
HES—57.4, CPRD—48.2; ON: HES—49.9, CPRD—
42.9). BP and ON had the lowest completeness of
recording and FS and GBS the highest. Most records
accrued within a year. When we added patients with a
ﬁrst record in CPRD, the increase in total completeness
was less than 10% (Appendix D).
Figure 4 illustrates data accrual patterns. BP and FS
accrued more quickly at initial stages and plateaued
sooner than the other outcomes. GBS showed a
steadier accrual pattern, plateauing at around 20 weeks
after HES recording. Sensitivity analyses using spe-
ciﬁc code lists showed similar patterns (Appendix E).
DISCUSSION
We have conducted a comprehensive analysis of
recording delays and completeness for four outcomes,
to inform NRTVSS. Our results showed that data
accrual patterns and completeness depend on the con-
ditions studied. Selecting conditions with different
characteristics (in clinical presentation, place of diag-
nosis and management) enabled us to capture these
different patterns. BP showed the quickest data accrual
and highest agreement between system and event date,
consistent with a condition often diagnosed and
Table 1. Gender, age and year of event date of included patients by condition
GBS (n = 830) BP (n = 12 602) ON (n = 1720) FS (n = 36 236)
Gender, n (%)
Male 465 (56.0) 6218 (49.3) 569 (33.1) 19 029 (52.5)
Female 365 (44.0) 6384 (50.7) 1151 (66.9) 17 207 (47.5)
Mean age (SD) 53.5 (20.1) 48.2 (20.2) 42.9 (17.8) 35.4 (29.0)
Year of event date, n (%)
2005 70 (8.4) 1317 (10.5) 187 (10.9) 3605 (9.9)
2006 98 (11.8) 1240 (9.8) 181 (10.5) 3774 (10.4)
2007 76 (9.2) 1275 (10.1) 191 (11.1) 3808 (10.5)
2008 100 (12.0) 1430 (11.3) 162 (9.4) 3989 (11.0)
2009 94 (11.3) 1407 (11.2) 175 (10.2) 3983 (11.0)
2010 84 (10.1) 1376 (10.9) 182 (10.6) 3853 (10.6)
2011 90 (10.8) 1390 (11.0) 196 (11.4) 3844 (10.6)
2012 96 (11.6) 1320 (10.5) 195 (11.3) 3923 (10.8)
2013 83 (10.0) 1251 (9.9) 166 (9.7) 3778 (10.4)
2014 39 (4.7) 596 (4.7) 85 (4.9) 1679 (4.6)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis; SD, standard deviation.
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managed by GPs. GBS and ON showed the slowest
data accrual. GBS is an acute condition usually requir-
ing admission, while ON is typically diagnosed and
managed in outpatient settings. We considered FS as
an acute condition diagnosed at any level of care, but
in most cases not requiring prolonged admission. This
is consistent with an intermediate agreement between
system and event date (38.1%) and more rapid data
accrual than GBS and ON. Overall, our ﬁndings indi-
cate that conditions diagnosed by GPs or during
short-term hospital admissions tend to accrue more
quickly than conditions diagnosed in hospital with
longer admission or diagnosed in outpatients. In gen-
eral, data captured in CPRD accrued within the ﬁrst
month of the diagnosis, making NRTVSS possible
using this data source.
Our assessment of completeness showed that a low
proportion of diagnoses ﬁrst recorded in HES subse-
quently accrued in CPRD. It seems particularly
unlikely that GPs are aware of <50% of cases of
serious conditions such as GBS. A recent UK study
that contacted GPs about patients with a coded GBS di-
agnosed in HES found that 68.2% (95% conﬁdence
interval: 60.7–74.9%) were aware of a GBS diagnosis
made in hospital that has been conﬁrmed (Julia Stowe,
personal communication). Incomplete diagnostic cod-
ing in general practice may occur because GPs instead
scan in hospital letters or record diagnoses in free text,
neither of which is now available to researchers using
CPRD because of changes in the information gover-
nance environment in the UK. This might have
decreased the ability to assess fully the validity of
CPRD data for research purposes. The inclusion of
therapy codes might help to capture some incompletely
coded diagnoses for conditions requiring treatment, but
the conditions we examined do not have unique treat-
ments. On the other hand, HES is itself an imperfect
source to capture conditions of interest as it might in-
clude unconﬁrmed cases. If that is the case, our analy-
sis would have underestimated completeness in CPRD.
For NRTVSS, if completeness is constant over time,
this should not bias the results, but it decreases power.
Knowing whether there is enough power is a key as-
pect when considering a new data source to implement
NRTVSS. This goes beyond the scope of our study but
should be assessed by future work looking at trial
Table 2. Cumulative distribution of delays by condition (n (%))
Delay* GBS (n = 830) BP (n = 12 602) ON (n = 1720) FS (n = 36 236)
Same day 275 (33.1) 9076 (72.0) 478 (27.8) 14 254 (39.3)
First week 371 (44.7) 10 459 (83.0) 699 (40.6) 22 181 (61.2)
First month 611 (73.6) 11 776 (93.4) 1310 (76.2) 31 031 (85.6)
6 months 790 (95.2) 12 431 (98.6) 1672 (97.2) 35 575 (98.2)
1 year 830 (100.0) 12 602 (100.0) 1720 (100.0) 36 236 (100.0)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis.
*Deﬁned as the difference between the system and the event date.
Figure 3. Weekly data accrual in CPRD across 52 weeks considering data accrued during the ﬁrst year and diagnosis made up to June 2014. BP, Bell’s palsy;
CPRD, Clinical Practice Research Datalink; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis
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implementation of NRTVSS using CPRD. Results
from that work will allow further conclusions on the
possibility of implementing NRTVSS using CPRD. A
further consideration is that, for conditions which
may not always require hospital admission, hospital-
ized patients may be a particular subset of all cases,
for example, those with more severe disease (as
highlighted in studies of upper gastrointestinal bleed-
ing and venous thromboembolism14,20) or speciﬁc pa-
tient characteristics (as in our study, which showed
that patients with BP and ON captured in HES were
older). This will matter if the adverse event is more
likely among these speciﬁc subgroups.
Previous adjustments for accrual delays when
conducting NRTVSS with administrative claims data
have focused on delays in processing information for
ﬁling and approval.12 Primary care-based data have
different sources of delay, and our work focused on
delays in practices documenting feedback from
secondary care. Our work thus differs from Greene
et al.12 in the reasons for the delays we have
considered. In addition, we looked at four outcomes
(GBS, BP, ON and FS), while Greene et al.12 have
only considered GBS. Other sources of delay include
time before data are made available; CPRD data are re-
leased to researchers monthly and practices upload
Table 3. Characteristics of included patients, time of follow-up and completeness of records in Clinical Practice Research Datalink per condition of interest
GBS (n = 678) BP (n = 4060) ON (n = 485) FS (n = 8321)
Gender, n (%)
Male 363 (53.5) 1844 (45.4) 155 (32.0) 4662 (56.0)
Female 315 (46.5) 2216 (54.6) 330 (68.0) 3659 (44.0)
Mean age (SD) 55.8 (21.0) 57.4 (24.1) 49.9 (25.2) 34.8 (31.2)
Year of diagnosis,* n (%)
2005 61 (9.0) 424 (10.4) 56 (11.5) 1264 (15.2)
2006 73 (10.8) 460 (11.3) 45 (9.3) 1108 (13.3)
2007 79 (11.7) 400 (9.9) 47 (9.7) 1103 (13.3)
2008 85 (12.5) 417 (10.3) 47 (9.7) 1055 (12.7)
2009 79 (11.7) 515 (12.7) 56 (11.5) 912 (11.0)
2010 69 (10.2) 545 (13.4) 68 (14.0) 793 (9.5)
2011 76 (11.2) 471 (11.6) 48 (9.9) 702 (8.4)
2012 71 (10.5) 404 (10.0) 56 (11.5) 715 (8.6)
2013 69 (10.2) 358 (8.8) 54 (11.1) 531 (6.4)
2014 16 (2.4) 66 (1.6) 8 (1.6) 138 (1.7)
Median follow-up time (years) 0.9 1.9 2.1 1.4
Completeness, % (95% conﬁdence interval)†
Maximum 45.9 (41.5–50.5) 26.8 (25.0–28.7) 28.5 (22.9–35.0) 46.0 (44.8–47.2)
At 1 year 41.3 (37.6–45.3) 22.1 (20.8–23.5) 22.4 (18.9–26.5) 41.8 (40.7–42.9)
BP, Bell’s palsy; FS, febrile seizures; GBS, Guillain–Barré syndrome; ON, optic neuritis; SD, standard deviation.
*Considering the start of episode date in Hospital Episode Statistics database.
†Kaplan–Meier estimates of individuals with a record in Clinical Practice Research Datalink.
Figure 4. Kaplan–Meier recording estimates considering a ﬁrst record in HES and a subsequent record in CPRD, truncated at 1 year. BP, Bell’s palsy; CPRD,
Clinical Practice Research Datalink; FS, febrile seizures; GBS, Guillain–Barré syndrome; HES, Hospital Episode Statistics; ON, optic neuritis
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data some time before each release. These delays
could be examined by looking at the time between last
collection date and date of release, and adjustments
made depending on the patterns of such delays. Delays
in making diagnoses could involve identifying early
symptom codes, with the extent of delay varying by
condition. The results of our study indicate that
adjustments for data accrual delays should be tailored
for individual conditions and that future studies should
consider including setting-speciﬁc adjustments, that is,
generating delay distributions for diagnoses made in
primary care, in-patient and outpatient settings. More
broadly, we recommend that researchers reﬂect on
the source of delays in their data and whether these
delays are likely to be dependent on the outcomes
of interest, to help decide whether to establish
condition-speciﬁc data accrual patterns.
To the best of our knowledge, this is the ﬁrst in-depth
analysis of recording delays in CPRD. Sammon and
Petersen13 recently examined the number of records
lost as a function of last collection date, to inform inci-
dence or prevalence studies. Our study complements
and extends this work by quantifying delays for
selected conditions and investigating how their charac-
teristics affect delays. Our study is novel in showing
the limitations of using system dates, and we have
proposed a simple approach to minimize the effects
of these limitations that are relevant to those planning
surveillance using CPRD. We also provide the ﬁrst
analyses of both completeness and timeliness of
recording of these four speciﬁc conditions in CPRD.
This study is subject to some limitations. Firstly,
measurement error in delays in stand-alone CPRD
may have resulted from errors in system and event
dates. We addressed misclassiﬁcation of system dates
by excluding dates that were likely to have been part
of mass transfers. As we did not take an unduly low
threshold, we may have included some transferred sys-
tem dates and thus overestimated delays. However,
our exclusion of delays >1 year should have mini-
mized this issue. Furthermore, if the same criteria are
applied to a future NRTVSS, inclusion of these re-
cords should not bias results. The event date is also
an imperfect measure of the date of diagnosis. When
entering diagnoses made elsewhere, GPs might insert
the diagnosis date, but alternatively, the date of hospi-
tal admission or discharge, the date the hospital letter
was received or the date of data entry. For the latter
three scenarios, our delays (the difference between
system and event dates) would be underestimated.
However, if this coding behaviour is constant over
time, any adjustments made in the future considering
our results would be valid. Furthermore, the choice
of code lists affects the validity of cases. We did not
validate the code lists directly, but assessed the poten-
tial effects of imperfect validity by using code lists
with different levels of sensitivity. The use of a more
speciﬁc code list did not substantially affect our re-
sults. When implementing a new system, this should
be further assessed; previous analyses suggest that a
more sensitive code list might produce more timely re-
sults.18 Finally, we did not quantify the uncertainty
around the data accrual estimates in CPRD. However,
our sensitivity analysis describing yearly patterns
showed stable results, suggesting it is appropriate to
use our distributions for future adjustments.
In conclusion, this work shows that most diagnoses
recorded in stand-alone CPRD accrued within the
ﬁrst month, making NRTVSS possible. The distribu-
tion of delays was condition-speciﬁc, and the weekly
delay distribution could be used to adjust for delays
in the NRTVSS analysis. CPRD can be a viable data
source to use in this kind of analysis; next steps will
include trial implementation of the system using
these data.
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KEY POINTS
• Near real-time vaccine safety surveillance using
electronic health records is one of the methods
available to detect vaccine safety signals. It
requires timely data.
• The Clinical Practice Research Datalink (CPRD)
is a potential data source for this surveillance.
• Delays in recording of events in CPRD will limit
its utility, and delays were found to vary by
condition. For Bell’s palsy and febrile seizures,
events were recorded sooner than for Guillain–
Barré syndrome and optic neuritis. For all these
conditions, most events documented by practices
were recorded within the ﬁrst month of the
presumed diagnosis date.
• Records of Guillain–Barré syndrome, Bell’s
palsy, optic neuritis and febrile seizures
diagnosed in hospital have low completeness of
recording in CPRD, with less than 50% recorded
within a year of the hospital admission date.
• The CPRD is a feasible data source to implement
near real-time surveillance, although sensitivity
of recording of events ﬁrst seen at hospital may
be low.
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